John E. Tellew
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Mechanisms and Therapy, Colorectal Cancer Treatments and Studies, Synthesis and Catalytic Reactions, Advanced Breast Cancer Therapies
Most-Cited Works
- → RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation(2013)123 cited
- → Identification of a High-Affinity Ligand That Exhibits Complete Aryl Hydrocarbon Receptor Antagonism(2011)104 cited
- → Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2‘-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics(2004)86 cited
- → Stereocontrolled Synthesis of the Tetracyclic Core of the Bisguanidine Alkaloids Palau'amine and Styloguanidine(1997)80 cited
- → Dehydroamino acid derivatives from D-arabinose and L-serine: synthesis of models for the azinomycin antitumor antibiotics(1993)63 cited
- → Stereocontrolled Synthesis of Triazacyclopenta[cd]pentalenes by Intramolecular 1,3-Dipolar Cycloaddition Reactions of Azomethine Imines(2002)54 cited
- → Discovery of N-Isoxazolyl Biphenylsulfonamides as Potent Dual Angiotensin II and Endothelin A Receptor Antagonists(2002)53 cited
- → Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor(2012)53 cited
- → Novel Dual Action AT1 and ETA Receptor Antagonists Reduce Blood Pressure in Experimental Hypertension(2004)51 cited
- → Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers(2017)44 cited